Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Caplan

Psychiatry Phoenix, AZ Medical Doctor

NPI 1538196456 CMS profile 342380

500 W Thomas Rd Ste 230, Phoenix, AZ 85013

Open in the dashboard

General payments

$998,640

1,163 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Caplan of Phoenix, AZ is reported in the CMS Open Payments database as having received $998,640 across 1,163 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $118,396 127
2024 General $123,249 159
2023 General $104,209 115
2022 General $105,708 114
2021 General $99,740 104
2020 General $120,939 152
2019 General $326,399 392

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Caplan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Jason Caplan were reported at $118,396. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Jason Caplan Psychiatry median Middle half National median
2019 $326,399 $184 $59–$605 $163
2020 $120,939 $119 $36–$372 $114
2021 $99,740 $143 $43–$576 $132
2022 $105,708 $153 $50–$590 $149
2023 $104,209 $170 $56–$651 $160
2024 $123,249 $179 $57–$673 $164
2025 $118,396 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $396,268 505 payments
  2. Avanir Pharmaceuticals, Inc. $238,159 211 payments
  3. ACADIA Pharmaceuticals Inc $183,896 226 payments
  4. Otsuka America Pharmaceutical, Inc. $112,484 167 payments
  5. E.R. Squibb & Sons, L.L.C. $53,462 48 payments
  6. Alkermes, Inc. $5,400 1 payment
  7. Sage Therapeutics, Inc. $5,040 1 payment
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $3,825 3 payments
  9. BioXcel Therapeutics, Inc. $106 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $709,855 306 payments
  2. Consulting Fee $147,282 45 payments
  3. Travel and Lodging $121,764 485 payments
  4. Food and Beverage $19,730 325 payments
  5. Education $9 2 payments
Products named General payments · program years 2019–2025
  1. NUEDEXTA pseudobulbar affect (PBA) $229,613 206 payments
  2. INGREZZA Neuropsychiatry $209,546 217 payments
  3. INGREZZA Neurology $135,992 229 payments
  4. NUPLAZID Parkinsons Disease Psychosis $134,546 168 payments
  5. NUEDEXTA Neurology $57,066 82 payments
  6. REXULTI $55,493 86 payments
  7. INGREZZA Neurology $50,730 59 payments
  8. NUPLAZID Parkinsons Disease Psychosis $41,434 53 payments
  9. COBENFY $24,072 28 payments
  10. NUPLAZID Pdp $7,915 5 payments
  11. Other $37,684 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$15,772

Medicare's payments for the services billed

Medicare patients

71

Average age 68

Services billed

252

27 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 55%
Diabetes 46%
Arthritis 44%
Alzheimer's or dementia 41%
Chronic kidney disease 35%
Ischemic heart disease 32%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
$51,872 — —
NUEDEXTA
$33,213 — —
REXULTI
$23,039 — —
COBENFY
$5,538 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,163 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record